TVTX Stock Recent News

TVTX LATEST HEADLINES

TVTX Stock News Image - globenewswire.com

NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. (“Travere” or the “Company”) (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

globenewswire.com 2025 Jun 23
TVTX Stock News Image - prnewswire.com

NEW YORK , June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

prnewswire.com 2025 Jun 22
TVTX Stock News Image - accessnewswire.com

NEW YORK, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

accessnewswire.com 2025 Jun 16
TVTX Stock News Image - accessnewswire.com

NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

accessnewswire.com 2025 Jun 13
TVTX Stock News Image - businesswire.com

SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on June 10, 2025, the Compensation Committee of its Board of Directors granted inducement equity grants to 15 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 81,100 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as in.

businesswire.com 2025 Jun 12
TVTX Stock News Image - prnewswire.com

NEW YORK , June 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ: TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

prnewswire.com 2025 Jun 12
TVTX Stock News Image - accessnewswire.com

NEW YORK, NY / ACCESS Newswire / June 11, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

accessnewswire.com 2025 Jun 11
TVTX Stock News Image - businesswire.com

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics today announced that the Company will present three abstracts at the upcoming International Podocyte Conference.

businesswire.com 2025 Jun 11
TVTX Stock News Image - businesswire.com

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics today announced the launch of a new awareness campaign, “Play It Forward,” to bring hope and encouragement to the FSGS community.

businesswire.com 2025 Jun 10
TVTX Stock News Image - accessnewswire.com

NEW YORK CITY, NY / ACCESS Newswire / June 9, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

accessnewswire.com 2025 Jun 09
10 of 50